Search Results

Your search for Gregory Bociek, MD, MSc,Gregory Bociek, MD, MSc matches 2 pages

Showing 1 - 2

By VIJAYA RAJ BHATT, MBBS, MS, AND R. GREGORY BOCIEK, MD, MSc / February 25, 2023 - Supplement: Conference Highlights ASH 2022 / 2022 ASH Annual Meeting and Exposition

Highlights From the 2022 ASH Annual Meeting and Exposition

The 2022 American Society of Hematology (ASH) Annual Meeting and Exposition took place in the vibrant city of New Orleans. The meeting brought together tens of thousands of participants from across the world to present and discuss the results of studies that ranged from hypothesis-generating to...

leukemia

By Gregory Bociek, MD, MSc / October 25, 2021

BTK Inhibition in CLL: An Embarrassment of Riches

Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder defined by a specific phenotype and the presence of more than 5,000 clonal B cells in the peripheral blood.1 In the absence of this number of circulating cells, its soft-tissue/bone-marrow counterpart is semantically...

Nov

Today In Oncology

Search Results

Your search for Gregory Bociek, MD, MSc,Gregory Bociek, MD, MSc matches 2 pages

Highlights From the 2022 ASH Annual Meeting and Exposition

BTK Inhibition in CLL: An Embarrassment of Riches

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

FDA Grants Accelerated Approval to Zanidatamab-hrii for Previously Treated Unresectable or Metastatic HER2-Positive Biliary Tract Cancer

Novel EGFR Inhibitor Firmonertinib Shows Activity in Rare Subtype of NSCLC

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma